The Tri-Fold Crisis: Why Modern Opioid Treatment Must Include Hepatitis C and HIV Screening

Introduction: A Broader View of the Opioid Crisis in 2026

Over the past decade, access to treatment for opioid use disorder (OUD) has improved significantly. Telemedicine, expanded prescribing authority, and increased public awareness have made it easier than ever for patients to begin treatment with medications like buprenorphine (Suboxone) and long-acting Sublocade injections. 

However, as access improves, a more complex systemic issue is becoming increasingly clear: treating opioid use disorder in isolation does not fully address the underlying health risks many patients face. Across high-impact regions like Miami-Dade County and Los Angeles, California, there is a growing recognition that OUD is inextricably linked with other serious infectious diseases—particularly Hepatitis C (HCV) and HIV.

According to data from the Centers for Disease Control and Prevention (CDC), this intersection represents what is now known as the “Tri-Fold Crisis”:

1. Opioid Use Disorder (OUD)
2. Hepatitis C (HCV)
3. HIV

Addressing one without the others leads to missed diagnoses, delayed care, and increased long-term health complications that burden both the individual and the public health infrastructure.

Why Treating OUD Alone is Clinically Incomplete

Many individuals with a history of opioid use, especially those with a history of injectable substances and incarceration, have been exposed to blood-borne infections. In many cases, integrated MAT Hep C screening is the only way to identify these conditions before they progress to late-stage disease.

The Overlap is Significant

• Hepatitis C Prevalence: In certain populations with prior injection drug use (IDU), HCV prevalence can exceed 70%.
• HIV Risk: Transmission risks remain elevated in communities where OUD is prevalent, particularly in dense urban environments.
• Asymptomatic Progression: Both HCV and HIV can remain asymptomatic for years. A patient may feel biologically stable on buprenorphine while an underlying infection progresses silently.

Without proactive HIV screening in opioid use disorder telehealth models, these conditions are often identified only when treatment becomes significantly more complex and outcomes less predictable.

The Long-Term Impact on Medicaid and Medi-Cal Systems

From a public health and systems perspective, delayed diagnosis carries massive fiscal consequences. In both Florida and California, public health systems—including the Medi-Cal substance use treatment framework—bear the high cost of late-stage disease management.

Health and Fiscal Consequences

• Untreated Hepatitis C: Can lead to chronic liver disease, cirrhosis, and liver cancer. The California Department of Public Health notes that early intervention with Direct-Acting Antivirals (DAAs) is significantly more cost-effective than managing end-stage liver failure.
• Untreated HIV: Results in immune system compromise and increased community transmission. Data from the Los Angeles County Department of Public Health shows that “Treatment as Prevention” (TasP) is only possible through early and consistent screening.

Early screening and treatment are now recognized not just as clinical best practices, but as the only sustainable way to manage the Los Angeles opioid crisis and Miami-Dade opioid crisis long-term.

Local Public Health Impact: Miami-Dade and Los Angeles

In high-density urban environments, the “Tri-Fold Crisis” requires a localized, infrastructure-aware approach.

Miami-Dade County: The HIV Epicenter

Miami-Dade continues to manage one of the highest HIV burdens in the United States. Florida Department of Health reports emphasize that substance use patterns in South Florida are a primary driver of new infections. Integrating telehealth Hep C screening and HIV testing into MAT is a critical component of the “Ending the HIV Epidemic” (EHE) initiative in Florida.

Los Angeles County: Scaling the Challenge

The Los Angeles opioid crisis involves a massive population density and significant fentanyl-related mortality. With a large Medi-Cal population, California has moved toward the CalAIM initiative, which seeks to integrate behavioral health with physical health. For California opioid treatment programs, success is measured by how well they connect OUD patients to infectious disease care during their initial window of engagement.

A Public Systems Perspective: Efficiency Through Integration

From a public administration standpoint, healthcare delivery must focus on system efficiency. When care is fragmented, patients are forced to navigate multiple silos: substance use treatment, infectious disease clinics, and primary care. This is where Suboxone treatment and pharmacy coordination become critical in ensuring patients receive uninterrupted care without delays.

In reality, expecting a patient in early recovery to schedule separate lab appointments and navigate complex systems often leads to failure.

• Re-entry Populations: Those recently released from incarceration are at the highest risk, particularly during the 72-hour treatment gap in re-entry populations, when continuity of care often breaks down.
• Urban Risk: High-density areas in Miami and Los Angeles see faster transmission rates when infections go undiagnosed.

Coordination ensures that screening occurs during existing touchpoints, treatment pathways are cleared, and long-term community outcomes improve.

The Role of Integrated Care Models

There is increasing momentum toward models that bring multiple elements of care together. At DevotedDOc, we believe the next phase of telemedicine must be more than just a prescription—it must be a comprehensive health gatekeeper.

Characteristics of Integrated Care:

• Universal Screening: Testing for HCV and HIV during initial OUD evaluations.
• Simplified Lab Access: Utilizing coordinated testing options, including local labs or at-home collection, to reduce patient burden—paired with Suboxone treatment and pharmacy coordination to ensure timely access to care.
• Result Continuity: Systems that ensure results are reviewed by the MAT provider and addressed immediately via “warm handoffs” to specialists.
• Medi-Cal Alignment: Ensuring all screening and treatment protocols meet the rigorous requirements of California MAT programs.

Clinical Perspective: The Physician’s Role

By Dr. Matthew Berrios

In clinical practice, the moment a patient engages in treatment for opioid use disorder is a “golden window.” They are motivated, they are connected to a provider, and they are focused on their health.

Screening for HCV and HIV during this period is a clinical imperative. It allows us to:

1. Diagnose Earlier: Identifying infections years before they become symptomatic.
2. Protect the Community: Reducing the “viral load” in the community by initiating treatment for HIV and curing HCV.
3. Treat the Whole Patient: Understanding that OUD does not exist in a vacuum.

As a Physician deeply involved in the community, I see the results of “fragmented care” every day—patients who arrive with liver failure or advanced HIV who were “on Suboxone” for years but were never screened. We must do better.

Conclusion: A More Complete Approach to Care

The progress made in expanding access to OUD treatment is significant. However, the next evolution of care depends on our ability to address the “Tri-Fold Crisis” proactively. For patients, this means fewer missed diagnoses and more complete care. For healthcare systems in Los Angeles and Miami-Dade, it means better outcomes and more efficient use of public resources.

As we move forward in 2026, integrated MAT Hep C screening will become the standard of care—ensuring that “recovery” means a return to total health, not just the absence of opioid use. 

Frequently Asked Questions

References & Public Health Resources

• Centers for Disease Control and Prevention (CDC): HIV and Viral Hepatitis Data
• California Department of Public Health (CDPH): Substance Use and Overdose Prevention
• Los Angeles County Department of Public Health: Substance Abuse Prevention and Control
• Florida Department of Health: HIV/AIDS Section
• Miami-Dade County Health Department: Integrated Behavioral Health Programs
• National Institute on Drug Abuse (NIDA): Drug Use and Viral Infections